Bipolar Depression Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Developments

Bipolar Depression Overview

Bipolar disorder is a disabling chronic disease in which depression usually presents a higher risk of long-term functional impairment than mania. Persistent depression does not have a known cause. As with bipolar disorder, depression has hereditary factors and might also involve neurotransmitter imbalances in the brain.

“Bipolar Depression Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bipolar Depression Market.

The Bipolar Depression Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Bipolar Depression Pipeline Report:

• Companies across the globe are diligently working toward developing novel Bipolar Depression treatment therapies with a considerable amount of success over the years. Bipolar Depression Key players such as – Clexio Biosciences, Iltoo Pharma, SAGE Therapeutics, NeuroRx, Inc., Sumitomo Dainippon Pharma, and others, are developing therapies for the Bipolar Depression treatment 

• Bipolar Depression Emerging therapies such as – CLE-100, ILT101, Zuranolone, NRX101, NRX100, SEP-4199, and others are expected to have a significant impact on the Bipolar Depression market in the coming years.   
• In January 2022, NeuroRx initiated multi-center, randomized, double-blind, trial in which patients with moderate levels of bipolar depression (MADRS >20) and subacute levels of suicidal ideation (C-SSRS 2 or 3) are randomized to receive twice daily oral NRX-101 or lurasidone (standard of care)
• In December 2020, Big Rock Partners Acquisition Corp. announces that it has entered into an Agreement and Plan of Merger with NeuroRx, Inc. Under the terms of the transaction, Big Rock and NeuroRx will merge and the company is expected to continue to tradeon the Nasdaq Stock Market under the symbol “NRXP
• In December 2019, NeuroRx initiated multi-center, randomized, stratified, double-blind, adaptive trial conducted under a Special Protocol Agreement with the FDA that enrolls patients demonstrating successful response in NCT03396601

Route of Administration

Bipolar Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal 
• Subretinal
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Bipolar Depression Pipeline Therapeutics Assessment

• Bipolar Depression Assessment by Product Type
• Bipolar Depression By Stage and Product Type
• Bipolar Depression Assessment by Route of Administration
• Bipolar Depression By Stage and Route of Administration
• Bipolar Depression Assessment by Molecule Type
• Bipolar Depression by Stage and Molecule Type

DelveInsight’s Bipolar Depression Report covers around 6+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Bipolar Depression Therapeutics Market include:

Key companies developing therapies for Bipolar Depression are – Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways and others

Emerging Bipolar Depression Drugs Under Different Phases of Clinical Development Include:

• CLE-100: Clexio Biosciences
• ILT101: Iltoo Pharma
• Zuranolone: SAGE Therapeutics
• NRX101: NeuroRx, Inc.
• NRX100: NeuroRx, Inc.
• SEP-4199: Sumitomo Dainippon Pharma

Get a Free Sample PDF Report to know more about Bipolar Depression Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight

Bipolar Depression Pipeline Analysis:

The Bipolar Depression pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Bipolar Depression with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bipolar Depression Treatment.
• Bipolar Depression key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bipolar Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bipolar Depression market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Bipolar Depression product details are provided in the report. Download the Bipolar Depression pipeline report to learn more about the emerging Bipolar Depression therapies

Bipolar Depression Pipeline Market Drivers

• Demand of new technologies
• Increase in the awareness regarding mental disorders

Bipolar Depression Pipeline Market Barriers

• Fewer randomized controlled trials (RCTs) of acute Bipolar Depression
• Strict pricing and reimbursement policies

Scope of Bipolar Depression Pipeline Drug Insight    

• Coverage: Global
• Key Bipolar Depression Companies: Clexio Biosciences, Iltoo Pharma, SAGE Therapeutics, NeuroRx, Inc., Sumitomo Dainippon Pharma, and others
• Key Bipolar Depression Therapies: CLE-100, ILT101, Zuranolone, NRX101, NRX100, SEP-4199, and others
• Bipolar Depression Therapeutic Assessment: Bipolar Depression current marketed and Bipolar Depression emerging therapies
• Bipolar Depression Market Dynamics: Bipolar Depression market drivers and Bipolar Depression market barriers 

Request for Sample PDF Report for Bipolar Depression Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Bipolar Depression drugs and therapies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services